The use of serological tumor markers for malignant melanoma

Oncology Research and Treatment

Volumn 20, Issue 6, 1997, Pages 462-465

  Hauschild, Axel ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

Melanoma; Metastasis; S100; Tumor markers; Tyrosinase PCR

Indexed keywords

CYSTEINYLDOPA; CYTOKINE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 8; MELANOMA ANTIGEN; MONOPHENOL MONOOXYGENASE; NEURON SPECIFIC ENOLASE; PROTEIN S 100; SIALIC ACID; TUMOR MARKER;

ADULT; ANTIGEN EXPRESSION; ARTICLE; BLOOD LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRACTICE GUIDELINE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0031409669     PISSN: 22965270     EISSN: None     Source Type: Journal    
DOI: 10.1159/000219008     Document Type: Article

References (33)

1. Klapdor R: Überlegungen zu einem sinnvollen Einsatz von Tumormarkern. Onkologe 1995:1:627-633.
2. Gläser R: Tumormarker des malignen Melanoms; in Garbe C. Dummer R. Kaufmann R. Tilgen W (Hrsg): Dermatologische Onkologie. Berlin. Springer. 1997, pp 324-329.
3. Chu TM: Prostate-specific antigen: in Sell S (ed): Serological Cancer Markers. Totowa. Humana Press. 1992. pp 99-115.
4. Hossfeld DK: Tumor marker terrorism. Educational Book; 21. Congress European Society of Medical Oncology (ESMO); 1.-5.11.1996: Wien, pp 191-192.
5. Pohl AL: Multiple testing with cancer markers: in Sell S (ed): Serological Cancer Markers Totowa. Humana Press 1992, pp 473-494.
6. Scheibenbogen C, Möhler T, Hacfcle J, Hunstein W, Keilholz U: Serum interleukin-8 (IL-8) is elevated in patients with metastatic melanoma and correlated with tumor load. Melanoma Res 1995:5:179-181.
7. Dummer W, Becker JC, Schwaaf A, Leverkus M, Moll T, Bröcker EB: Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. Melanoma Res 1995:5:67-68.
8. Altomonte M, Colizzi F, Esposito G, Maio M: Circulating intercellular adhesion molecule 1 as a marker of disease progression in cutaneous melanoma. N Engl J Med 1992:327:959.
9. Viac J, Misery L, Schmitt D, Gaudy A: Follow-up of circulating 1CAM-1 in malignant melanoma: Correlation with the clinical course of the disease. Br J Dermatol 1996:134:604-605.
10. Hornef S, Lux J, Rassner G: NSE - Ein geeigneter Tumormarker des malignen Melanoms? Hautarzt 1992:43:77-80.
11. Buzaid AC, Sandler AB, Hayden Clark-Level, Scinto J, Poo WJ, Clark MB, Hotchkiss S: Neuron-specific enolase as a tumor marker in metastatic melanoma. Am J Clin Oncol 1994;17:430-431.
12. Couvreur R, Joos G, Geerts M-L, Lambert J, Naeyaert J-M: Neuron-specific enolase as serum marker for malignant melanoma. Lancet 1993:342:985.
13. Wibe E, Hannisdal E, Paul E, Aamdal S: Neuron-specific enolase as a prognostic factor in metastatic malignant melanoma. Fur J Cancer 1992;28A: 1692-1695.
14. Reinigen DS, Cruse CW, Wells KE, Saba HI, Fabri PJ: The evaluation of putative tumor markers for malignant melanoma. Ann Plastic Surgery 1992:28: 55-59.
15. Miliotes G, Lyman GH, Cruse CW, Puleo C, Alber-tini J, Rapaport D, Glass F, Fenske N, Soriano T, Cuny C, VanVoorhis N, Reinigen D: Evaluation of new putative tumor markers for melanoma. Ann Surg Oncol 1996:3:558-563.
16. Moore BW: A soluble protein characteristic of the nervous system. Biochem Biophys Res Commun 1965:19:739-744.
17. Guo HB, Stoffel-Wagner B, Bierwirth T, Mezger J, Klingmüller D: Clinical significance of serum S100 in metastatic malignant melanoma. Eur J Cancer 1995;31:924-928.
18. Henze G, Dummer R, Joller-Jemelka HI, Böni R, Burg G: Serum SI00 - A marker for disease monitoring in metastatic melanoma. Dermatology 1997: 194:208-212.
19. von Schoultz E, Hansson LO, Djureen E, Hansson J, Kärnell R, Nilsson B, Stigbrand T, Ringborg U: Prognostic value of serum analyses of S-100ß protein in malignant melanoma. Melanoma Res 1996:6: 133-137.
20. Buer J, Probst M, Franzke A, Duensing S, Haindl J, Volkenandt M, Wittke F, Hoffmann R, Ganser A, Atzpodien J: Elevated serum levels of SI00 and survival in metastatic malignant melanoma. Br J Cancer 1997:75:1373-1376.
21. Hein R, Bosserhoff AK, Stolz W, Kaufmann M, Kaluza B, Buettner R: MIA scrum levels as a detection and monitoring system of malignant melanoma. Arch Dermatol Res 1997:289:A30.
22. Horikoshi T, Ito S, Wakamatsu K, Onodera H, Eguchi H: Evaluation of melanin-related metabolites as markers of melanoma progression. Cancer 1994:73:629-636.
23. Smith B, Selby P, Southgate J, Pittman K, Bradley C, Blair GE: Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 1991:338:1227-1229.
24. Brossart P, Keilholz U, Willhauck M, Scheibenbogen C, Möhler T, Hunstein W: Hematogenous spread of malignant melanoma cells in different stages of disease. J Invest Dermatol 1993:10: 887-889.
25. Brossart P, Schmier MW, Krüger S, Willhauck M, Scheibenbogen C, Möhler T, Keilholz U: A polymerase chain reaction-based semiquantitative assessment of malignant melanoma cells in peripheral blood. Cancer Res 1995:55:4065-4068.
26. Battayani Z, Grob JJ, Xerri L, Noe C, Zarour H, Houvaeneghcl G, Delpero JR, Brimbaum D, Hassoun J, Bonerandi JJ: Polymerase chain reaction detection o: circulating melanocytes as a prognostic marker in patients with melanoma. Arch Dermatol 1995;131:443-447.
27. Kunter U, Buer J, Probst M, Duensing S, Dallmann I, Grosse J, Kirchner H, Schluepen EM, Volkenandt M, Ganser A, Atzpodien J: Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanoma. J Natl Cancer Inst 1996:88: 590-594.
28. Tobal K, Sherman LS, Foss AJE, Lightman SL: Detection of melanocytes from uveal melanoma in peripheral blood using the polymerase chain reaction. Invest Ophthalmol Vis Sei 1993:34:2622-2625.
29. Mellado B, Colomer D, Castel T, Munoz M, Carballo E, Galan M, Mascaro JM, Vivcs-Corrons JL, Grau JJ, Estape J: Detection of circulating neoplastic cells by reverse-transcriptase polymerase chain reaction in malignant melanoma: Association with clinical stage and prognosis. J Clin Oncol 1996:14: 2091-2097.
30. Gläser R, Rass K, Seiter S, Hauschild A, Christophers E, Tilgen W: Detection of circulating melanoma cells by specific amplification of tyrosinase complementary DNA is not a reliable tumor marker in melanoma patients: A clinical two-center study. J Clin Oncol 1997;15:2818-2825.
31. Hoon DSB, Wang Y, Dale PS, Conrad AJ, Schmid P, Garrison D, Kuo C, Foshag LJ, Nizze AJ, Morton DL: Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay.; Clin Oncol 1995:13:2109-2116.
32. Pittman K, Burchill S, Smith B, Southgate J, Joffe J, Gore M, Selby P: Reverse transcriptase-polymerase chain reaction for expression of tyrosinase to identify malignant melanoma cells in peripheral blood. Ann Oncol 1996:7:297-301.
33. Reinhold U, Lüdtke-Handjery HC, Schnautz S, Kreysel H-W, Abken H: The analysis of tyrosinase-specific mRNA in blood samples of melanoma patients by RT-PCR is not a useful test for metastatic tumor progression. J Invest Dermatol 1997:108: 166-169.